These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 38531621

  • 21. Synbiotics, prebiotics and probiotics for people with chronic kidney disease.
    Cooper TE, Khalid R, Chan S, Craig JC, Hawley CM, Howell M, Johnson DW, Jaure A, Teixeira-Pinto A, Wong G.
    Cochrane Database Syst Rev; 2023 Oct 23; 10(10):CD013631. PubMed ID: 37870148
    [Abstract] [Full Text] [Related]

  • 22. Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND.
    van Vollenhoven RF, Hall S, Wells AF, Meerwein S, Song Y, Tanjinatus O, Fleischmann R.
    RMD Open; 2024 Jul 24; 10(3):. PubMed ID: 39053948
    [Abstract] [Full Text] [Related]

  • 23. Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.
    Merola JF, Gottlieb AB, Pinter A, Elewski B, Gooderham M, Warren RB, Piaserico S, Wixted K, Cross N, Tilt N, Wiegratz S, Mrowietz U.
    Dermatol Ther (Heidelb); 2024 Dec 24; 14(12):3291-3306. PubMed ID: 39578348
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.
    Fleischmann R, Meerwein S, Charles-Schoeman C, Combe B, Hall S, Khan N, Carter KM, Camp HS, Rubbert-Roth A.
    RMD Open; 2024 Jul 25; 10(3):. PubMed ID: 39059811
    [Abstract] [Full Text] [Related]

  • 25. Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment.
    Mease PJ, Gottlieb AB, Ogdie A, McInnes IB, Chakravarty SD, Rampakakis E, Kollmeier A, Xu XL, Shawi M, Lavie F, Kishimoto M, Rahman P.
    Clin Rheumatol; 2024 Jan 25; 43(1):241-249. PubMed ID: 37787903
    [Abstract] [Full Text] [Related]

  • 26. Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial.
    Ramiro S, Lukas C, Nissen MJ, Zhu B, Ng KJ, Sheesh M, Doridot G, Liu-Leage S, Chan A, Fang Y, Wei JC.
    Semin Arthritis Rheum; 2024 Dec 25; 69():152571. PubMed ID: 39509838
    [Abstract] [Full Text] [Related]

  • 27. Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.
    Idowu M, Otieno L, Dumitriu B, Lobo CLC, Thein SL, Andemariam B, Nnodu OE, Inati A, Glaros AK, Bartolucci P, Colombatti R, Taher AT, Abboud MR, Darbari D, Ataga KI, Antmen AB, Kuo KHM, de Souza Medina S, Oluyadi A, Iyer V, Morris S, Yates AM, Shao H, Patil S, Urbstonaitis R, Zaidi AU, Gheuens S, Smith WR.
    Lancet Haematol; 2024 Dec 04. PubMed ID: 39644907
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial.
    Zhang H, Li Q, Li C, Wu M, Chen H, Li Y, You F, Zhao Y, Jin J, Chen X, Ding Y.
    Lancet Rheumatol; 2024 Dec 04; 6(12):e837-e847. PubMed ID: 39454617
    [Abstract] [Full Text] [Related]

  • 29. Relationship of psoriatic arthritis with nail and scalp involvement in Turkish psoriasis patients: Multicentered cross-sectional study.
    Askin O, Engin B, Ozdede A, Kartal SP, Ugurlu S, Akbulut TO, Ekinci AP, Aydogdu İH, Ozden MG, Kok H, Dogan S, Ozturkcan S, Borlu M, Baskan EB, Yilmaz N, Ak T, Topkarci Z, Serdaroglu S.
    Medicine (Baltimore); 2024 Jul 19; 103(29):e38832. PubMed ID: 39029037
    [Abstract] [Full Text] [Related]

  • 30. Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial.
    Askanase AD, D'Cruz D, Kalunian K, Merrill JT, Navarra SV, Cahuzac C, Cornelisse P, Murphy MJ, Strasser DS, Trokan L, Berkani O.
    Lancet Rheumatol; 2024 Nov 22. PubMed ID: 39586304
    [Abstract] [Full Text] [Related]

  • 31. Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial.
    Sun Y, Lv Q, Guo Y, Wang Z, Huang R, Gao X, Han Y, Yao Z, Zheng M, Luo S, Li Y, Gu X, Zhang Y, Wang J, Hong L, Ma X, Su G, Sheng J, Lai C, Shen A, Wang M, Zhang W, Wu S, Zheng Z, Li J, Zhong T, Wang Y, He L, Du X, Ma CS.
    J Am Coll Cardiol; 2024 Nov 12; 84(20):2037-2047. PubMed ID: 39505412
    [Abstract] [Full Text] [Related]

  • 32. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.
    Ritchlin CT, Mease PJ, Boehncke WH, Tesser J, Schiopu E, Chakravarty SD, Kollmeier AP, Xu XL, Shawi M, Jiang Y, Sheng S, Wang Y, Xu S, Merola JF, McInnes IB, Deodhar A.
    RMD Open; 2022 Mar 12; 8(1):. PubMed ID: 35296534
    [Abstract] [Full Text] [Related]

  • 33. Cryotherapy following total knee replacement.
    Aggarwal A, Adie S, Harris IA, Naylor J.
    Cochrane Database Syst Rev; 2023 Sep 14; 9(9):CD007911. PubMed ID: 37706609
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
    Gladman DD, Mease PJ, Bird P, Soriano ER, Chakravarty SD, Shawi M, Xu S, Quinn ST, Gong C, Leibowitz E, Poddubnyy D, Tam LS, Helliwell PS, Kavanaugh A, Deodhar A, Østergaard M, Baraliakos X.
    Trials; 2022 Sep 05; 23(1):743. PubMed ID: 36064592
    [Abstract] [Full Text] [Related]

  • 35. Telemonitoring of Active Inflammatory Bowel Disease Using the App TECCU: Short-Term Results of a Multicenter Trial of GETECCU.
    Aguas M, Del Hoyo J, Vicente R, Barreiro-de Acosta M, Melcarne L, Hernandez-Camba A, Madero L, Arroyo MT, Sicilia B, Chaparro M, Martin-Arranz MD, Pajares R, Mesonero F, Mañosa M, Martinez P, Chacón S, Tosca J, Marín S, Sanroman L, Calvo M, Monfort D, Saiz E, Zabana Y, Guerra I, Varela P, Baydal V, Faubel R, Corsino P, Porto-Silva S, Brunet E, González M, Gutiérrez A, Nos P.
    J Med Internet Res; 2024 Nov 18; 26():e60966. PubMed ID: 39189160
    [Abstract] [Full Text] [Related]

  • 36. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C, Ni H, Aung HH.
    Cochrane Database Syst Rev; 2024 Aug 12; 8(8):CD014869. PubMed ID: 39132750
    [Abstract] [Full Text] [Related]

  • 37. Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials.
    Norton H, Sliwinska-Stanczyk P, Hala T, El-Zorkany B, Stockert L, Mundayat R, Wang L, Ritchlin CT.
    Rheumatol Ther; 2024 Dec 05. PubMed ID: 39636343
    [Abstract] [Full Text] [Related]

  • 38. Brodalumab: Six-Year US Pharmacovigilance Report.
    Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL, Mangin GD, Jacobson AA.
    Dermatol Ther (Heidelb); 2024 Nov 26. PubMed ID: 39589679
    [Abstract] [Full Text] [Related]

  • 39. Traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trial.
    Guo J, Chen X, Wu M, Wang D, Zhao Y, Li Q, Tang G, Che F, Xia Z, Liang Z, Shi L, Jiang Q, Chen Y, Liu X, Ren X, Ouyang M, Wang B, You S, Billot L, Wang X, Liu Z, Jing H, Meng W, Tian S, Liu E, Xiang Y, Tang X, Xie T, Cui W, Zheng Y, Cao J, Zhang J, Wen Z, Huang T, Wang L, You C, Pan S, Cai Y, Lu Y, Hankey GJ, Al-Shahi Salman R, Anderson CS, Song L, CHAIN investigators.
    Lancet; 2024 Nov 30; 404(10468):2187-2196. PubMed ID: 39547249
    [Abstract] [Full Text] [Related]

  • 40. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
    Edwards SJ, Karner C, Jhita T, Barton S, Marceniuk G, Yiu ZZN, Wittmann M.
    Health Technol Assess; 2024 Jan 30; 28(4):1-113. PubMed ID: 38343072
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.